X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15217) 15217
Newsletter (42) 42
Magazine Article (34) 34
Book Chapter (11) 11
Book / eBook (10) 10
Dissertation (6) 6
Conference Proceeding (5) 5
Publication (4) 4
Newspaper Article (2) 2
Web Resource (2) 2
Book Review (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11467) 11467
female (6382) 6382
male (5792) 5792
animals (5466) 5466
interleukin-2 - therapeutic use (4440) 4440
middle aged (4078) 4078
immunology (3938) 3938
adult (3910) 3910
interleukin-2 (3900) 3900
mice (3855) 3855
oncology (3573) 3573
immunotherapy (3542) 3542
aged (2677) 2677
cancer (2049) 2049
lymphocytes (1701) 1701
cytokines (1665) 1665
interleukin-2 - administration & dosage (1631) 1631
treatment outcome (1489) 1489
expression (1454) 1454
t-lymphocytes - immunology (1437) 1437
medicine, research & experimental (1367) 1367
antibodies, monoclonal - therapeutic use (1361) 1361
therapy (1357) 1357
t cells (1353) 1353
transplantation (1172) 1172
antineoplastic agents - therapeutic use (1170) 1170
mice, inbred c57bl (1170) 1170
antineoplastic combined chemotherapy protocols - therapeutic use (1157) 1157
interleukin-2 - immunology (1128) 1128
t-lymphocytes, regulatory - immunology (1119) 1119
interleukin-2 - pharmacology (1048) 1048
recombinant proteins - therapeutic use (1045) 1045
combined modality therapy (1044) 1044
melanoma (1036) 1036
mice, inbred balb c (1034) 1034
interleukin-2 - metabolism (1024) 1024
surgery (1024) 1024
killer cells, natural - immunology (1014) 1014
flow cytometry (1005) 1005
hematology (975) 975
cells, cultured (968) 968
interleukin-2 - adverse effects (960) 960
pharmacology & pharmacy (957) 957
lymphocyte activation (953) 953
care and treatment (940) 940
recombinant interleukin-2 (926) 926
research (924) 924
t-cells (918) 918
health aspects (914) 914
adolescent (895) 895
neoplasms - therapy (893) 893
activation (865) 865
cd4-positive t-lymphocytes - immunology (849) 849
immunosuppressive agents - therapeutic use (848) 848
dendritic cells (834) 834
interleukin-2 - biosynthesis (818) 818
time factors (816) 816
il-2 (812) 812
interleukin-2 - genetics (786) 786
immunotherapy - methods (774) 774
kidney neoplasms - therapy (770) 770
cells (760) 760
interleukin 2 (751) 751
carcinoma, renal cell - therapy (732) 732
rats (724) 724
cell biology (722) 722
kidney neoplasms - drug therapy (720) 720
in-vivo (700) 700
carcinoma, renal cell - drug therapy (697) 697
melanoma - therapy (697) 697
analysis (678) 678
lymphocytes t (668) 668
metastatic melanoma (667) 667
melanoma - drug therapy (661) 661
chemotherapy (660) 660
lymphocyte activation - drug effects (651) 651
induction (649) 649
survival (649) 649
interferon-alpha - therapeutic use (643) 643
drug therapy, combination (636) 636
antigens (629) 629
interferon (617) 617
research article (611) 611
prognosis (610) 610
regulatory t-cells (604) 604
tumors (602) 602
kidney neoplasms - pathology (596) 596
neoplasms - immunology (595) 595
interleukin-2 - blood (593) 593
dose-response relationship, drug (590) 590
disease models, animal (583) 583
interferon-alpha (579) 579
neoplasm metastasis (578) 578
inflammation (568) 568
receptors, interleukin-2 - immunology (568) 568
cd8-positive t-lymphocytes - immunology (564) 564
tumor cells, cultured (560) 560
clinical trials as topic (551) 551
interleukin-2 receptor alpha subunit - metabolism (545) 545
t-lymphocytes - drug effects (544) 544
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14687) 14687
Japanese (274) 274
Chinese (206) 206
French (140) 140
German (121) 121
Russian (85) 85
Spanish (40) 40
Italian (38) 38
Polish (32) 32
Portuguese (9) 9
Dutch (6) 6
Czech (5) 5
Finnish (4) 4
Hungarian (4) 4
Hebrew (3) 3
Norwegian (2) 2
Romanian (2) 2
Swedish (2) 2
Turkish (2) 2
Croatian (1) 1
Danish (1) 1
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
European urology, ISSN 0302-2838, 2017, Volume 71, Issue 3, pp. 426 - 436
...), the most effective therapeutic approach for patients with non-clear cell RCC (non-ccRCC) is unknown. Objective To systematically review relevant literature comparing... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | carcinoma | Review | Non-clear cell renal cell | Journal Article | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Clinical Medicine | Cancer and Oncology | Urology and Nephrology | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article
Journal of oral and maxillofacial surgery, ISSN 0278-2391, 2013, Volume 71, Issue 9, pp. 1532 - 1540
Purpose To investigate the efficacy and safety of zoledronic acid (ZA) combined with targeted therapy (TT). Materials and Methods A retrospective study was... 
Surgery | SURVIVAL | PROSTATE | ADHESION | BISPHOSPHONATES | CANCER-PATIENTS | NECROSIS | DENTISTRY, ORAL SURGERY & MEDICINE | SKELETAL-RELATED EVENTS | SUNITINIB | BREAST | PROGRESSION | Niacinamide - analogs & derivatives | Follow-Up Studies | Humans | Middle Aged | Interleukin-2 - therapeutic use | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Angiogenesis Inhibitors - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Retrospective Studies | Bone Neoplasms - drug therapy | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Diphosphonates - adverse effects | Everolimus | Molecular Targeted Therapy - methods | Radiography, Panoramic | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Bone Density Conservation Agents - adverse effects | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Fractures, Spontaneous - etiology | Survival Rate | Spinal Cord Compression - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Carcinoma, Renal Cell - secondary | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Cohort Studies | Care and treatment | Trade and professional associations | Metastasis
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 68, Issue 3, pp. 516 - 522
Abstract Background Limited data exist on the economic consequences of implementing targeted therapy (TT) for metastatic renal cell carcinoma (RCC) in a... 
Urology | Metastatic renal cell carcinoma | Economic analysis | Population-based | Observational | National | Targeted therapy | Cost analysis | Implementation | 1ST-LINE TREATMENT | COST-EFFECTIVENESS | FINLAND | EVEROLIMUS | SUNITINIB MALATE | CANCER | INTERFERON-ALPHA | IMMUNOTHERAPY | 2ND-LINE TREATMENT | UROLOGY & NEPHROLOGY | Bevacizumab - therapeutic use | Everolimus - economics | Radiotherapy - economics | Humans | Middle Aged | Niacinamide - economics | Male | Antineoplastic Agents - therapeutic use | Efficiency | Employment - economics | Aged, 80 and over | Sirolimus - economics | Indoles - economics | Bevacizumab - economics | Costs and Cost Analysis | Protein Kinase Inhibitors - economics | Niacinamide - therapeutic use | Antineoplastic Agents - economics | Carcinoma, Renal Cell - economics | Indoles - therapeutic use | Ambulatory Care - economics | Phenylurea Compounds - economics | Drug Costs | Niacinamide - analogs & derivatives | Fluorouracil - economics | Interleukin-2 - economics | Interleukin-2 - therapeutic use | Immunologic Factors - economics | Fluorouracil - therapeutic use | Neoplasm Metastasis - drug therapy | Angiogenesis Inhibitors - therapeutic use | Adult | Angiogenesis Inhibitors - economics | Everolimus - therapeutic use | Female | Registries | Pyrroles - economics | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Radiography - economics | Interferon-alpha - therapeutic use | Interferon-alpha - economics | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - economics | Health Care Costs | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Denmark | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Hospitalization - economics | Immunologic Factors - therapeutic use | Economic aspects | Metastasis | Carcinoma, Renal cell
Journal Article
Cancer science, ISSN 1349-7006, 2019, Volume 110, Issue 7, pp. 2080 - 2089
Regulatory T (Treg) cells suppress abnormal/excessive immune responses to self‐ and nonself‐antigens to maintain immune homeostasis. In tumor immunity, Treg... 
immune suppression | tumor | tolerance | immune checkpoint | Treg | DENDRITIC CELLS | REG CELLS | RECEPTOR | INDUCTION | FOXP3 | TUMOR-IMMUNITY | EFFECTOR | ONCOLOGY | AUTOIMMUNE-DISEASE | EXPRESSION | Interleukin-2 - metabolism | Small Molecule Libraries - pharmacology | Immunotherapy - methods | Cytokines - metabolism | Humans | Small Molecule Libraries - therapeutic use | CTLA-4 Antigen - metabolism | Antineoplastic Agents - therapeutic use | Antineoplastic Agents, Immunological - pharmacology | Neoplasms - drug therapy | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Regulatory - drug effects | Animals | Interleukin-2 Receptor alpha Subunit - metabolism | Antineoplastic Agents, Immunological - therapeutic use | Neoplasms - immunology | Protein Kinase Inhibitors - therapeutic use | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Autoimmunity | Development and progression | Dendritic cells | T cells | Health aspects | Cancer | CD86 antigen | Effector cells | Homeostasis | Cytotoxicity | Lymphocytes T | Metastases | Metabolites | Precision medicine | Lymphocytes | Immunotherapy | CD25 antigen | Tumor necrosis factor-TNF | Vascular endothelial growth factor | CCL17 protein | Antigens | Adenosine | Cell survival | Cytokines | Immunoregulation | Therapeutic applications | Autoantigens | CD80 antigen | CXCR3 protein | Metabolism | Patients | Chemokine receptors | Immune checkpoint | Antitumor activity | CCR8 protein | Autoimmune diseases | Chemokines | Review
Journal Article
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 3, pp. 511 - 517
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2006, Volume 24, Issue 35, pp. 5601 - 5608
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 01/2017, Volume 2017, Issue 1, pp. CD004759 - CD004759
Background Prolonging kidney transplant survival is an important clinical priority. Induction immunosuppression with antibody therapy is recommended at... 
Kidney disease | Acute Disease | Immunosuppressive Agents | Cytomegalovirus Infections | Induction therapy/primary immunosuppression | Kidney Transplantation | Alemtuzumab | Antibodies, Monoclonal | Randomized Controlled Trials as Topic | Antibodies, Monoclonal, Humanized | Calcineurin Inhibitors | Muromonab‐CD3 | Immunosuppression | Kidney transplant | Child health | TRANSPLANTATION: KIDNEY | Graft Rejection | Induction therapy / primary immunosuppression | Antilymphocyte Serum | Antibody therapy | Medicine General & Introductory Medical Sciences | Receptors, Interleukin‐2 | Steroids | DOSE RATG INDUCTION | MEDICINE, GENERAL & INTERNAL | ANTI-THYMOCYTE GLOBULIN | RENAL-ALLOGRAFT RECIPIENTS | CALCINEURIN-INHIBITOR WITHDRAWAL | RANDOMIZED CLINICAL-TRIAL | RAPID STEROID WITHDRAWAL | AZATHIOPRINE-ANTILYMPHOCYTE GLOBULIN | RABBIT ANTITHYMOCYTE GLOBULIN | IMMEDIATE TACROLIMUS THERAPY | 3 IMMUNOSUPPRESSIVE REGIMENS | Muromonab-CD3 - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Immunosuppression - methods | Graft Rejection - prevention & control | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Receptors, Interleukin-2 - immunology | Calcineurin Inhibitors - therapeutic use | Graft Rejection - mortality | Antilymphocyte Serum - therapeutic use | Cytomegalovirus Infections - etiology | Immunosuppressive Agents - adverse effects | Kidney Transplantation - mortality | Steroids - therapeutic use | Antilymphocyte Serum - adverse effects | Kidney Transplantation - adverse effects | Index Medicus
Journal Article